FAM
SYRE icon

Fred Alger Management’s Spyre Therapeutics SYRE Stock Holding History

Fred Alger Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Sell
28,834
-30,619
-52% -$2.23M 0.01% 298
2026
Q1 		$3M Buy
+59,453
New +$2.24M 0.01% 280
2024
Q2 		– Sell
-18,158
Closed -$689K – 471
2024
Q1 		$689K Buy
+18,158
New +$526K ﹤0.01% 382

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Fred Alger Management's SYRE Position: Q2 2026 in Review

Fred Alger Management reduced its Spyre Therapeutics (SYRE) stake by 52% in Q2 2026, selling an estimated $2.23M and leaving 28,834 shares worth $2.56M. The position accounts for 0.01% of the portfolio, ranked #298.

Fred Alger Management first reported a position in SYRE in Q1 2024 and has held it in 3 quarters since. The position peaked at $3M in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Fred Alger Management held 28,834 shares of Spyre Therapeutics worth $2.56M as of Q2 2026.
  • Fred Alger Management sold 30,619 Spyre Therapeutics shares in Q2 2026, an estimated $2.23M.
  • Spyre Therapeutics made up 0.01% of Fred Alger Management's portfolio in Q2 2026, its #298 holding.
  • Fred Alger Management first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Fred Alger Management's Spyre Therapeutics position peaked at $3M in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.